LGT Group Foundation Has $54.02 Million Holdings in Pfizer Inc. $PFE

LGT Group Foundation increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 27.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,985,137 shares of the biopharmaceutical company’s stock after acquiring an additional 423,419 shares during the quarter. LGT Group Foundation’s holdings in Pfizer were worth $54,016,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of PFE. Peak Asset Management LLC grew its position in shares of Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after purchasing an additional 402 shares in the last quarter. Community Bank & Trust Waco Texas raised its position in shares of Pfizer by 0.6% in the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after buying an additional 412 shares in the last quarter. CVA Family Office LLC boosted its stake in shares of Pfizer by 3.3% in the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after buying an additional 413 shares during the period. Boltwood Capital Management boosted its stake in shares of Pfizer by 0.7% in the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock valued at $1,485,000 after buying an additional 420 shares during the period. Finally, Beverly Hills Private Wealth LLC grew its position in Pfizer by 1.5% during the third quarter. Beverly Hills Private Wealth LLC now owns 27,955 shares of the biopharmaceutical company’s stock worth $712,000 after buying an additional 421 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug (Xianweiying / ecnoglutide), opening a large new market for its obesity franchise and reinforcing Pfizer’s push into metabolic drugs — this expands addressable market and supports long‑term revenue potential. China approves Pfizer GLP-1 drug for weight management
• Positive Sentiment: Analyst upgrade: Argus Research upgraded PFE to Buy and set a $35 target, citing progress in the GLP‑1 program and oncology pipeline — this can attract buy interest and boost sentiment among dividend and income investors. Argus Turns Bullish on Pfizer
• Positive Sentiment: Oncology wins: positive Phase 3 EV‑304 PADCEV results and FDA full approval for BRAFTOVI combinations were highlighted as re‑framing Pfizer’s long‑term growth prospects in oncology — supports diversification away from COVID revenues. Pfizer Obesity Nod In China And Cancer Wins
• Positive Sentiment: Pipeline expansion in China: Pfizer launched a Phase 1 heart‑failure candidate study in China, signaling continued local R&D investment that could yield future launches in a large market. Pfizer Adds New Early-Stage Heart Failure Candidate
• Neutral Sentiment: Investor attention & valuation debate: multiple articles note heightened retail/institutional interest and divergent valuation views (trending stock coverage, DCF vs. long‑term return debates) — increases volatility/volume but not a direct fundamental change. Pfizer Is a Trending Stock
• Neutral Sentiment: Competition & generics risk for GLP‑1s: coverage notes Pfizer will face crowded competition (and price pressure risk) even as it gains approvals — a mixed commercial outlook. Weight-Loss Drug Approved in China — Up Against Generic Rivals
• Negative Sentiment: Structural headwinds remain: analysts reiterate risks from declining COVID revenues, upcoming patent expirations and U.S. drug‑pricing pressures (IRA) that could limit near‑term growth despite new launches. Can Pfizer Reignite Growth?
• Negative Sentiment: Policy/legal noise: a recent court ruling awarded Pfizer $29M in an SEC settlement dispute (one‑time benefit), but legal and policy developments remain sources of uncertainty for investors. Judge approves Pfizer, SEC settlement

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Morgan Stanley dropped their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Barclays initiated coverage on Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, February 4th. UBS Group began coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective for the company. Finally, Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $28.05.

Pfizer Trading Up 1.7%

Shares of PFE stock opened at $27.07 on Monday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The stock’s fifty day moving average price is $26.30 and its two-hundred day moving average price is $25.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The company has a market cap of $153.93 billion, a PE ratio of 19.90 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.63 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Friday, January 23rd were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer’s dividend payout ratio is 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.